Unexplained Anemia and Cancer: When Low Blood Counts Are a Warning Sign

Anemia — defined as a hemoglobin below 13.0 g/dL in men and 12.0 g/dL in women — is one of the most common abnormalities found on routine blood work. In most cases, the explanation is straightforward: iron-poor diet, heavy menstrual bleeding, vitamin B12 or folate deficiency, or chronic kidney disease suppressing red blood cell production. Clinicians see it constantly, the cause is usually clear, and treatment is uncomplicated.

But anemia is also the single most common blood abnormality in cancer. Approximately 40% of all cancer patients develop anemia at some point during their illness. In certain malignancies — multiple myeloma, leukemia, and colorectal cancer — anemia is present at diagnosis in the majority of patients, often as the only finding that precedes other symptoms by weeks to months.

The clinical problem is pattern recognition. Iron deficiency anemia caused by a diet of white rice and minimal protein looks identical on a basic blood count to iron deficiency caused by a bleeding colorectal tumor. Both show low hemoglobin and low red cell volume. The difference emerges only when the clinician asks: who is this patient, does this fit their demographic, and does this anemia behave the way an ordinary dietary deficiency should? This article explains the mechanisms by which cancer causes anemia, the specific patterns associated with different malignancies, and the alarm features that should trigger investigation rather than empiric supplementation.

How Cancer Causes Anemia: The 6 Mechanisms

Understanding why cancer causes anemia is the foundation for recognizing suspicious patterns. There are six distinct mechanisms, each producing a different blood count picture.

• Occult GI bleeding → iron deficiency anemia. The most clinically consequential mechanism. Colorectal, gastric, and esophageal cancers can bleed slowly and intermittently — producing iron deficiency long before any GI symptom appears. The bleeding is often imperceptible: no frank blood in stool, no abdominal pain. Yet the accumulation depletes iron stores enough to produce severe anemia — a microcytic, hypochromic picture indistinguishable from dietary deficiency without further context.
• Hepcidin-driven iron sequestration → anemia of chronic disease (ACD). Tumors generate systemic inflammation that triggers the liver to release hepcidin — a hormone that locks iron inside macrophages and intestinal cells, making it unavailable for red blood cell production even when stores are adequate. The result: normocytic, normochromic anemia with normal or elevated ferritin and low serum iron. This is the most common anemia pattern among established cancer patients.
• Intrinsic factor loss / B12 malabsorption → megaloblastic anemia. Gastric cancer destroys the parietal cells that produce intrinsic factor, the protein required for B12 absorption. Over time, B12 stores deplete, producing macrocytic anemia. Myelodysplastic syndrome (MDS) also produces macrocytic anemia — but through defective stem cell maturation that cannot be corrected with B12 or folate.
• Bone marrow infiltration → leukoerythroblastic anemia. When cancer cells colonize the marrow, they displace normal blood-forming tissue and force immature cells prematurely into circulation. The peripheral blood smear shows teardrop red cells, nucleated red blood cells, immature white cells (myelocytes), and giant platelets — a pattern called leukoerythroblastic anemia. This is a major alarm sign for marrow infiltration.
• Autoimmune destruction → hemolytic anemia. Certain lymphoid malignancies — particularly CLL and non-Hodgkin lymphoma — trigger antibodies that attack the patient’s own red blood cells. Warm autoimmune hemolytic anemia (AIHA) causes progressive anemia, jaundice, and dark urine. Laboratory signs: elevated LDH, elevated indirect bilirubin, low haptoglobin, positive Coombs test.
• Marrow replacement → pancytopenia. Acute leukemia and advanced lymphoma flood the marrow with malignant cells, suppressing all three cell lines simultaneously — anemia, thrombocytopenia, and neutropenia together. Circulating blasts may appear on the peripheral smear in acute leukemia.

Iron Deficiency Anemia: The GI Bleeding Red Flag

Iron deficiency is the most common cause of anemia globally. In young premenopausal women, the cause is almost always menstrual blood loss or dietary insufficiency, and cancer investigation is not routinely required. The calculus changes completely in two groups:

Men of any age with iron deficiency anemia have no physiological mechanism for iron loss. Postmenopausal women have lost their menstrual explanation. In both groups, British Society of Gastroenterology guidelines (Goddard AF, Gut 2011) mandate upper GI endoscopy and colonoscopy — regardless of whether GI symptoms are present.

The reason is colorectal cancer. Right-sided colon cancers bleed intermittently into the bowel lumen, causing iron depletion without changing stool color or caliber. Between 60–70% of colorectal cancer patients have anemia at diagnosis — many presenting with hemoglobin in the 9–10 g/dL range and nothing else. By the time GI symptoms appear, the cancer may already be locally advanced.

Gastric cancer produces iron deficiency through direct bleeding from tumor ulceration and through hypochlorhydria — gastric acid is required for non-heme iron absorption, and acid suppression by tumor invasion impairs it. Esophageal cancers at the gastroesophageal junction similarly bleed and present with IDA.

The critical teaching point: a microcytic anemia in a man or postmenopausal woman that does not respond to iron supplementation within 4–6 weeks does not need a higher dose of iron. It needs an endoscope.

Anemia of Chronic Disease: The Normocytic Pattern

Normocytic anemia — normal red cell size (MCV 80–100 fL), hemoglobin modestly reduced, typically 9–12 g/dL — is the most common anemia pattern in cancer overall. It results from chronic inflammation, not nutrient deficiency or bleeding.

The mechanism: IL-6 and TNF-α produced by the tumor stimulate hepcidin release, blocking iron recycling from macrophages. Simultaneously, inflammatory cytokines shorten red blood cell survival and blunt the bone marrow’s response to erythropoietin. The key laboratory distinction from iron deficiency: in ACD, ferritin is normal or elevated (ferritin is an acute-phase reactant), serum iron is low, and TIBC is also low — unlike iron deficiency, where TIBC rises as the body tries to capture more iron.

Any of the following findings warrants investigation beyond empiric treatment in patients over 50:

• Weight loss, night sweats, or drenching sweats
• Lymphadenopathy or splenomegaly on examination
• Elevated LDH or ESR without infectious explanation
• Abnormal calcium, renal function, or total protein
• Fatigue disproportionate to the hemoglobin level

CT imaging, SPEP, and abdominal palpation for organomegaly are the appropriate next steps in unexplained normocytic anemia in the at-risk population.

Macrocytic Anemia and Myelodysplastic Syndrome

An elevated MCV (above 100 fL) triggers a B12 and folate check — and rightly so. Alcohol excess and hypothyroidism also cause macrocytosis. But when B12, folate, TSH, and alcohol history are all unremarkable, a malignant cause must enter the differential.

Gastric cancer destroys the parietal cells that produce intrinsic factor, leading to B12 malabsorption accumulating silently over years. A patient with B12 deficiency who has no dietary explanation — not vegetarian, not elderly with known atrophic gastritis — warrants upper endoscopy, particularly if epigastric symptoms, early satiety, or weight loss accompany the finding.

Myelodysplastic syndrome (MDS) is a pre-leukemic bone marrow disorder predominantly affecting adults over 65. It presents as refractory macrocytic anemia — declining gradually over months, not responding to B12 or folate replacement because the defect is in the marrow stem cells themselves. Approximately 30% of MDS cases progress to acute myeloid leukemia. The critical red flag: macrocytic anemia that fails to respond to B12 and folate replacement within 6–8 weeks requires bone marrow biopsy.

Leukoerythroblastic Anemia: The Most Alarming Pattern

The peripheral blood smear is one of the most powerful and underused diagnostic tools in medicine. When a smear shows leukoerythroblastic changes, it changes everything.

The pattern includes:

• Teardrop cells (dacrocytes) — red cells deformed by a fibrotic or infiltrated marrow
• Nucleated red blood cells — erythroid precursors released prematurely from disrupted marrow
• Immature myeloid cells — myelocytes and metamyelocytes that should not appear in peripheral blood
• Giant or hypogranular platelets — released under demand stress

This pattern is not a lab artifact and is not caused by nutritional deficiency. It reflects mechanical disruption of normal marrow architecture by infiltrating cells. In an adult, it is malignancy until proven otherwise.

Responsible cancers: breast (the most common solid tumor to metastasize to marrow), prostate, lung (especially small cell), multiple myeloma, lymphoma with marrow involvement, and acute leukemia. When leukoerythroblastic changes appear, bone marrow biopsy is urgent. CT or PET-CT to identify the primary tumor runs in parallel.

Multiple Myeloma: Anemia as the Presenting Feature

Multiple myeloma is systematically delayed in diagnosis — the average time from first symptom to diagnosis is over a year — and anemia is its most common presenting finding, present in over 70% of patients at diagnosis.

The myeloma constellation:

• Normocytic anemia — often Hgb 9–11 g/dL, disproportionately symptomatic
• Bone pain — back, ribs, skull — from lytic lesions
• Hypercalcemia — nausea, constipation, polyuria, cognitive slowing
• Renal impairment — from light chain deposition
• Elevated protein gap (total protein minus albumin >4 g/dL)
• Rouleaux formation on smear — RBCs stacking like coins from excess paraprotein
• Very high ESR — often >100 mm/hr
• Monoclonal spike on SPEP — the diagnostic finding

The pattern that should always trigger SPEP: an elderly patient with normocytic anemia, bone pain at multiple sites, and either hypercalcemia, renal impairment, or an elevated protein gap. Any two of these findings in combination should prompt SPEP and urine protein electrophoresis (UPEP).

Red Flags: When Anemia Demands Cancer Investigation

Feature	Likely Benign	Demands Investigation
Sex / menstrual status	Premenopausal woman, heavy periods	Man or postmenopausal woman
Iron deficiency cause	Vegetarian diet, documented	Unexplained in men / postmenopausal
Blood smear	Normal morphology	Leukoerythroblastic, rouleaux, blasts, teardrops
Treatment response	Iron/B12 corrects anemia in 4–6 weeks	No response after adequate trial
Associated symptoms	None	Weight loss, night sweats, bone pain, lymphadenopathy
Other lab findings	Isolated anemia	Pancytopenia, hypercalcemia, elevated ESR, protein gap
Age	Under 50, identifiable cause	Over 50, any new unexplained anemia

Diagnostic Approach

First-tier (every unexplained anemia): CBC with differential and manual blood smear review, reticulocyte count (low = underproduction; elevated = hemolysis/bleeding), iron panel (serum iron, TIBC, ferritin), B12 and folate, CMP (calcium, renal function, LFTs), LDH, TSH.

Second-tier (age >50 or alarm features): SPEP (unexplained normocytic anemia in adults over 50), fecal immunochemical test (FIT) or FOBT (any IDA), ESR (very elevated in myeloma/lymphoma), haptoglobin and indirect bilirubin if hemolysis suspected.

Third-tier by pattern:

• IDA in men or postmenopausal women → upper GI endoscopy + colonoscopy (bidirectional)
• Leukoerythroblastic smear → urgent bone marrow biopsy + CT/PET-CT
• Macrocytic anemia not responding to B12/folate → bone marrow biopsy (MDS)
• Pancytopenia → urgent bone marrow biopsy
• Normocytic anemia with systemic symptoms → CT chest/abdomen/pelvis
• Hemolytic pattern + lymphadenopathy → CT + lymph node biopsy

Frequently Asked Questions

Can anemia be the first sign of cancer?

Yes — and it is more common than most patients realize. Right-sided colorectal cancer frequently presents as iron deficiency anemia before any GI symptom appears. Multiple myeloma presents with normocytic anemia in over 70% of cases at diagnosis. Lymphoma can produce anemia through several mechanisms before lymph nodes become enlarged. In many cases, a routine blood count showing low hemoglobin is the first and only early abnormality that triggers the investigation leading to diagnosis.

What type of anemia is most commonly associated with cancer?

Anemia of chronic disease — normocytic, normochromic — is the most common overall in cancer patients, found in approximately 40% during active illness. But iron deficiency anemia is the most important for early detection, because it prompts GI investigation that discovers colorectal, gastric, and esophageal cancers at potentially curable stages.

Should all iron deficiency anemia be investigated for cancer?

Not all. In premenopausal women with documented heavy periods or vegetarian diets, empiric iron treatment is appropriate. But in men of any age and postmenopausal women, iron deficiency has no physiological explanation and requires bidirectional GI endoscopy — regardless of whether GI symptoms are present.

What is leukoerythroblastic anemia?

A peripheral blood smear pattern showing teardrop red cells, nucleated red blood cells, and immature white cells — premature forms that should not appear in peripheral blood. This pattern reflects disruption of normal bone marrow architecture by infiltrating cancer cells. It is not a benign finding and requires urgent bone marrow biopsy.

How is cancer-related anemia different from regular anemia?

Cancer-related anemia may be indistinguishable from ordinary anemia on the basic CBC alone. The differentiating features: progressive decline without explanation, no response to iron or B12 after an adequate trial, abnormal blood smear findings, and associated systemic symptoms — weight loss, night sweats, lymphadenopathy, bone pain — along with laboratory abnormalities such as elevated LDH, abnormal serum protein, or hypercalcemia.

Which cancers are most commonly found when investigating unexplained anemia?

Colorectal cancer (found through GI investigation of IDA in men/postmenopausal women), multiple myeloma (found through SPEP in unexplained normocytic anemia with bone pain or protein abnormality), lymphoma (through imaging and biopsy in normocytic anemia with systemic symptoms), gastric cancer (via upper endoscopy), and leukemia/MDS (through bone marrow biopsy in pancytopenia or refractory macrocytic anemia).

Does treating the anemia improve cancer outcomes?

Treating anemia improves quality of life and treatment tolerance. But treating it empirically — without characterizing its cause — can delay cancer diagnosis by weeks to months. In colorectal cancer, localized disease carries a 5-year survival of over 90%; metastatic disease, around 15%. The anemia should be characterized before it is treated — both goals are achievable together, but the sequence matters.

The Bottom Line

Anemia is common and its common causes are benign. But a laboratory alone cannot separate benign from malignant anemia — only context, smear review, and targeted investigation can. A man of 60 with hemoglobin of 10 g/dL and low ferritin is not a dietary problem. An elderly woman with MCV of 106 and normal B12 is not an alcohol problem. A patient with teardrop cells and nucleated red cells on smear is not a hematology curiosity.

The step that changes outcomes is the decision to investigate rather than treat empirically. For colorectal cancer discovered through anemia workup at localized stage, survival exceeds 90%. For the same cancer discovered at metastatic stage, survival falls to around 15%. That gap is the clinical value of pattern recognition in an otherwise ordinary blood count.

When anemia does not fit its supposed explanation — when iron doesn’t respond as expected, when the smear is abnormal, when B12 was replaced but the MCV stayed elevated — the right response is investigation, not a higher supplement dose.